NASDAQ:ALBT Avalon GloboCare (ALBT) Stock Price, News & Analysis $3.13 -0.20 (-6.01%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Avalon GloboCare Stock (NASDAQ:ALBT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avalon GloboCare alerts:Sign Up Key Stats Today's Range$2.90▼$3.3650-Day Range$2.64▼$5.4952-Week Range$2.42▼$21.60Volume107,176 shsAverage Volume173,582 shsMarket Capitalization$3.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAvalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Read More… The secret supplier behind NVIDIA, Tesla and Microsoft (Ad)The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Avalon GloboCare Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks8th Percentile Overall ScoreALBT MarketRank™: Avalon GloboCare scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Avalon GloboCare.Read more about Avalon GloboCare's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalon GloboCare is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalon GloboCare is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Avalon GloboCare's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.49% of the float of Avalon GloboCare has been sold short.Short Interest Ratio / Days to CoverAvalon GloboCare has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalon GloboCare has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalon GloboCare does not currently pay a dividend.Dividend GrowthAvalon GloboCare does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.49% of the float of Avalon GloboCare has been sold short.Short Interest Ratio / Days to CoverAvalon GloboCare has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalon GloboCare has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.04 News SentimentAvalon GloboCare has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Avalon GloboCare this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 2 people have added Avalon GloboCare to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avalon GloboCare insiders have not sold or bought any company stock.Percentage Held by Insiders37.30% of the stock of Avalon GloboCare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.42% of the stock of Avalon GloboCare is held by institutions.Read more about Avalon GloboCare's insider trading history. Receive ALBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBT Stock News HeadlinesAvalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir SalesOctober 31 at 12:29 PM | markets.businessinsider.comAvalon GloboCare Corp. (NASDAQ:ALBT) Short Interest UpdateOctober 30 at 2:29 AM | americanbankingnews.comThe most productive 1 min of your day… This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.October 31, 2024 | Timothy Sykes (Ad)Avalon Globocare Corp trading halted, news pendingOctober 26, 2024 | markets.businessinsider.comAvalon GloboCare Corporation Announces 1-for-15 Reverse Stock SplitOctober 26, 2024 | americanbankingnews.comAvalon GloboCare Collaborates for Cannabis Breathalyzer DevelopmentOctober 25, 2024 | markets.businessinsider.comAvalon announces 1-for-15 reverse stock splitOctober 25, 2024 | markets.businessinsider.comEXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis BreathalyzerOctober 25, 2024 | msn.comSee More Headlines ALBT Stock Analysis - Frequently Asked Questions How have ALBT shares performed this year? Avalon GloboCare's stock was trading at $7.2450 at the beginning of 2024. Since then, ALBT shares have decreased by 56.8% and is now trading at $3.13. View the best growth stocks for 2024 here. How were Avalon GloboCare's earnings last quarter? Avalon GloboCare Corp. (NASDAQ:ALBT) announced its quarterly earnings results on Monday, August, 19th. The company reported ($2.85) EPS for the quarter. The business had revenue of $0.33 million for the quarter. When did Avalon GloboCare's stock split? Shares of Avalon GloboCare reverse split on the morning of Monday, October 28th 2024. The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Avalon GloboCare? Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avalon GloboCare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Mullen Automotive (MULN) and Intel (INTC). Company Calendar Last Earnings8/19/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALBT Previous SymbolNASDAQ:AVCO CUSIPN/A CIK1630212 Webwww.avalon-globocare.com Phone(732) 780-4400Fax732-780-5600Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,710,000.00 Net Margins-1,122.78% Pretax Margin-1,122.78% Return on EquityN/A Return on Assets-64.34% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$1.30 million Price / Sales28.55 Cash FlowN/A Price / Cash FlowN/A Book Value($1.15) per share Price / Book-2.90Miscellaneous Outstanding Shares11,105,000Free Float10,022,000Market Cap$36.98 million OptionableNot Optionable Beta0.31 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ALBT) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.